445 related articles for article (PubMed ID: 32884060)
21. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant.
Solano C; Slavin M; Shaul AJ; Marks DI; Cordonnier C; Cornely OA; Pagliuca A; Cragin L; Jarque I; Garcia-Vidal C; Sorensen S; Vanness DJ; Charbonneau C; Barrueta JA; Peral C; De Salas-Cansado M; Bow EJ
Mycoses; 2017 Feb; 60(2):79-88. PubMed ID: 27562016
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
23. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.
Wang J; Zhan P; Zhou R; Xu J; Shao X; Yang Y; Ouyang J
Med Oncol; 2010 Dec; 27(4):1082-8. PubMed ID: 19876778
[TBL] [Abstract][Full Text] [Related]
24. Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience.
Busca A; Cinatti N; Gill J; Passera R; Dellacasa CM; Giaccone L; Dogliotti I; Manetta S; Corcione S; De Rosa FG
Front Cell Infect Microbiol; 2021; 11():805514. PubMed ID: 35071052
[TBL] [Abstract][Full Text] [Related]
25. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients.
Playford EG; Webster AC; Sorrell TC; Craig JC
Cochrane Database Syst Rev; 2006 Jan; (1):CD004920. PubMed ID: 16437504
[TBL] [Abstract][Full Text] [Related]
26. Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.
Fortún J; Muriel A; Martín-Dávila P; Montejo M; Len O; Torre-Cisneros J; Carratalá J; Muñoz P; Fariñas C; Moreno A; Fresco G; Goikoetxea J; Gavaldá J; Pozo JC; Bodro M; Vena A; Casafont F; Cervera C; Silva JT; Aguado JM;
Liver Transpl; 2016 Apr; 22(4):427-35. PubMed ID: 26709146
[TBL] [Abstract][Full Text] [Related]
27. Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.
Gonzalez AV; Ullmann AJ; Almyroudis NG; Segal BH
J Natl Compr Canc Netw; 2008 Feb; 6(2):175-82. PubMed ID: 18319049
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTs.
Wang JF; Xue Y; Zhu XB; Fan H
Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):651-9. PubMed ID: 25502737
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.
O'Sullivan AK; Weinstein MC; Pandya A; Thompson D; Langston AA; Perfect JR; Papadopoulos G
Am J Health Syst Pharm; 2012 Jan; 69(2):149-56. PubMed ID: 22215361
[TBL] [Abstract][Full Text] [Related]
30. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis.
Chen L; Wang Y; Zhang T; Li Y; Meng T; Liu L; Hao R; Dong Y
BMC Infect Dis; 2018 Apr; 18(1):155. PubMed ID: 29609553
[TBL] [Abstract][Full Text] [Related]
31. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
Vardakas KZ; Michalopoulos A; Falagas ME
Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
[TBL] [Abstract][Full Text] [Related]
32. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
33. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.
Leonart LP; Tonin FS; Ferreira VL; Penteado STS; Wiens A; Motta FA; Pontarolo R
J Clin Pharm Ther; 2017 Oct; 42(5):530-538. PubMed ID: 28620958
[TBL] [Abstract][Full Text] [Related]
34. Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.
Ping B; Zhu Y; Gao Y; Yue C; Wu B
Ann Hematol; 2013 Jun; 92(6):831-9. PubMed ID: 23455400
[TBL] [Abstract][Full Text] [Related]
35. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.
Robenshtok E; Gafter-Gvili A; Goldberg E; Weinberger M; Yeshurun M; Leibovici L; Paul M
J Clin Oncol; 2007 Dec; 25(34):5471-89. PubMed ID: 17909198
[TBL] [Abstract][Full Text] [Related]
36. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.
Groll AH; Walsh TJ
Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576
[TBL] [Abstract][Full Text] [Related]
37. Nystatin prophylaxis and treatment in severely immunodepressed patients.
Gøtzsche PC; Johansen HK
Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD002033. PubMed ID: 25188770
[TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of Posaconazole vs. First-Generation Triazoles for the Prevention of Invasive Fungal Infections Among High-Risk Patients With Hematological Malignancies in China.
Shi C; Ye J; Xie Y; Dong R; Jin W; Wang L; Fang Y; Shan Q; Lin N
Front Public Health; 2022; 10():884846. PubMed ID: 35655452
[TBL] [Abstract][Full Text] [Related]
39. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant.
Alexander BD; Perfect JR; Daly JS; Restrepo A; Tobón AM; Patino H; Hardalo CJ; Graybill JR
Transplantation; 2008 Sep; 86(6):791-6. PubMed ID: 18813103
[TBL] [Abstract][Full Text] [Related]
40. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
